ArticleFrontiers in pharmacology2019
Resveratrol Protects Against Post-Contrast Acute Kidney Injury in Rabbits With Diabetic Nephropathy.
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Targeting integrated cell death networks in sepsis‑associated acute kidney injury: Shared regulatory nodes and diet‑related small molecule modulation (Review).International journal of molecular medicine · 2026Review
- Mechanisms of the Effects of Polyphenols on Diabetic Nephropathy.Current issues in molecular biology · 2025Review
- Mechanisms and therapeutic prospects of hypoxia-inducible factor 1-alpha in acute kidney injury: a systematic review.Frontiers in cell and developmental biology · 2025Review
- Assessment of Acute Kidney Injury using MRI.Journal of magnetic resonance imaging : JMRI · 2025Review
- Anthraquinones fromDrug design, development and therapy · 2025Review
- Assessment of renal pathophysiological processes and protective effect of quercetin on contrast-induced acute kidney injury in type 1 diabetic mice using diffusion tensor imaging.Redox report : communications in free radical research · 2024Article
- PGC1-α in diabetic kidney disease: unraveling renoprotection and molecular mechanisms.Molecular biology reports · 2024Review
- Endogenous and Exogenous Antioxidants as Agents Preventing the Negative Effects of Contrast Media (Contrast-Induced Nephropathy).Pharmaceuticals (Basel, Switzerland) · 2023Review
- Polyphenols and Their Metabolites in Renal Diseases: An Overview.Foods (Basel, Switzerland) · 2022Review
- The Pathophysiology and the Management of Radiocontrast-Induced Nephropathy.Diagnostics (Basel, Switzerland) · 2022Review
- Assessment of Fasudil on Contrast-Associated Acute Kidney Injury Using Multiparametric Renal MRI.Frontiers in pharmacology · 2022Article
- Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases.Frontiers in pharmacology · 2022Review
- Effects of Dietary Resveratrol Supplementation on Growth Performance and Anti-Inflammatory Ability in Ducks (Animals : an open access journal from MDPI · 2021Article
- Activators of SIRT1 in the kidney and protective effects of SIRT1 during acute kidney injury (AKI) (effect of SIRT1 activators on acute kidney injury).Clinical and experimental nephrology · 2021Review
- Prospective Pharmacological Potential of Resveratrol in Delaying Kidney Aging.International journal of molecular sciences · 2021Review
- Effects of resveratrol on the inflammatory response and renal injury in hyperuricemic rats.Nutrition research and practice · 2021Article
- Neuroprotective and Angiogenesis Effects of Levetiracetam Following Ischemic Stroke in Rats.Frontiers in pharmacology · 2021Article
- Mitochondrial Dysfunction and Diabetic Nephropathy: Nontraditional Therapeutic Opportunities.Journal of diabetes research · 2021Review
- Silencing of miR-150-5p Ameliorates Diabetic Nephropathy by Targeting SIRT1/p53/AMPK Pathway.Frontiers in physiology · 2021Article
- Resveratrol Modulates Transforming Growth Factor-Beta (TGF-β) Signaling Pathway for Disease Therapy: A New Insight into Its Pharmacological Activities.Biomedicines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resveratrol (Res) is a multi-functional polyphenol compound that has protective functions in acute kidney diseases. Here, we examined whether the resveratrol could ameliorate post-contrast acute kidney injury (PC-AKI) following diabetic nephropathy (DN), and explored any underlying mechanism(s)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.